当前位置: X-MOL 学术Islets › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Class IIa HDACs do not influence beta-cell function under normal or high glucose conditions.
Islets ( IF 2.2 ) Pub Date : 2019-05-21 , DOI: 10.1080/19382014.2019.1617621
Jacob McCann 1 , Megan Ellis 1 , Sean L McGee 1 , Kathryn Aston-Mourney 1
Affiliation  

Inhibiting Class IIa Histone Deacetylase (HDAC) function is a promising approach to therapeutically enhance skeletal and cardiac muscle metabolic health in several chronic diseases including type 2 diabetes. However, the importance of Class IIa HDACs in the beta-cell remains unknown. As beta-cell function is vital to maintaining glycaemia it is essential that the importance of Class IIa HDACs in the beta-cell is determined. Here we used the INS-1E cell line cultured in normal glucose (11.1 mM) or hyperglycaemic (20 mM) conditions for 48 hrs to represent cells in a normal and diabetic environment respectively. Cells cultured in high glucose showed significantly reduced insulin secretory function and increased apoptotic signalling compared to cells cultured in normal glucose. Class IIa HDACS, HDAC-4 and −5, were not regulated at the transcript or protein level under normal or hyperglycaemic conditions suggesting that they may not play a role in beta-cell dysfunction. Furthermore, overexpression of wild-type HDAC-4 and −5 or dominant negative HDAC-4 and −5 did not alter insulin secretion, insulin mRNA expression or apoptotic signalling under normal or hyperglycaemic conditions. This suggests that Class IIa Histone Deacetylases do not play an important physiological role in the beta-cell under normal or diabetic conditions. Thus, Class IIa Histone Deacetylase inhibitors are not likely to have a detrimental effect on beta-cells supporting the use of these inhibitors to treat metabolic diseases such as type 2 diabetes.



中文翻译:

IIa类HDAC在正常或高血糖条件下不影响β细胞功能。

抑制IIa类组蛋白脱乙酰基酶(HDAC)功能是在包括2型糖尿病在内的几种慢性疾病中增强骨骼和心肌代谢健康的有前途的方法。但是,IIa类HDAC在β细胞中的重要性仍然未知。由于β细胞功能对于维持血糖至关重要,因此必须确定IIa类HDAC在β细胞中的重要性。在这里,我们使用在正常葡萄糖(11.1 mM)或高血糖(20 mM)条件下培养48小时的INS-1E细胞系分别代表正常和糖尿病环境中的细胞。与在正常葡萄糖中培养的细胞相比,在高葡萄糖中培养的细胞显示出胰岛素分泌功能显着降低,并且凋亡信号转导增加。IIa类HDACS,HDAC-4和-5,在正常或高血糖情况下,其转录本或蛋白质水平均未受到调节,表明它们可能在β细胞功能异常中不起作用。此外,在正常或高血糖条件下,野生型HDAC-4和-5或显性阴性HDAC-4和-5的过表达不会改变胰岛素分泌,胰岛素mRNA表达或凋亡信号。这表明在正常或糖尿病条件下,IIa类组蛋白去乙酰化酶在β细胞中没有重要的生理作用。因此,IIa类组蛋白去乙酰化酶抑制剂不太可能对β细胞产生有害影响,从而支持使用这些抑制剂治疗2型糖尿病等代谢性疾病。在正常或高血糖情况下,野生型HDAC-4和-5的过表达或显性负HDAC-4和-5的表达不会改变胰岛素分泌,胰岛素mRNA表达或凋亡信号。这表明在正常或糖尿病条件下,IIa类组蛋白去乙酰化酶在β细胞中没有重要的生理作用。因此,IIa类组蛋白去乙酰化酶抑制剂不太可能对β细胞产生有害影响,从而支持使用这些抑制剂治疗2型糖尿病等代谢性疾病。在正常或高血糖情况下,野生型HDAC-4和-5的过表达或显性负HDAC-4和-5的表达不会改变胰岛素分泌,胰岛素mRNA表达或凋亡信号。这表明在正常或糖尿病条件下,IIa类组蛋白去乙酰化酶在β细胞中没有重要的生理作用。因此,IIa类组蛋白去乙酰化酶抑制剂不太可能对β细胞产生有害影响,从而支持使用这些抑制剂治疗2型糖尿病等代谢性疾病。这表明在正常或糖尿病条件下,IIa类组蛋白去乙酰化酶在β细胞中不发挥重要的生理作用。因此,IIa类组蛋白去乙酰化酶抑制剂不太可能对β细胞产生有害影响,从而支持使用这些抑制剂治疗2型糖尿病等代谢性疾病。这表明在正常或糖尿病条件下,IIa类组蛋白去乙酰化酶在β细胞中没有重要的生理作用。因此,IIa类组蛋白去乙酰化酶抑制剂不太可能对β细胞产生有害影响,从而支持使用这些抑制剂治疗2型糖尿病等代谢性疾病。

更新日期:2019-05-21
down
wechat
bug